Evaluation of a community-based memory clinic in collaboration with local hospitals to support patients with memory decline

Ali Elbeddini, PharmD a,*, Yasamin Tayefehchamani, PharmD b, Zekiye Yilmaz, PhD c, Josiah J. Villegas d and Eleen Y. Zhang e

a Winchester District Memorial Hospital, Winchester, ON, Canada
b Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
c Clinical Pharmacy Department, Acibadem University, Turkey
d University of Toronto, Leslie Dan Faculty of Pharmacy, Toronto, ON, Canada
e Ottawa, ON, Canada

Received 29 March 2021; revised 6 May 2021; accepted 9 May 2021; Available online 25 August 2021

Abstract

Objective: This study evaluates the role of a specialised and multidisciplinary healthcare team, including a pharmacist, in providing medication management for patients with mild cognitive impairment (MCI) and dementia, in a memory clinic.

Methods: The study analysed the dataset of 102 patients of a geriatric and memory clinic in a rural area of Ontario, Canada. The case histories of the patients were reviewed a week before the clinic day and a pharmacist performed medication reconciliations. During the clinic day, cognitive tests were conducted and outcomes were discussed with the team, to create a care plan and schedule a follow-up within 3, 6 or 12 months.

Results: Most patients had an average of 5 prescriptions and 2 non-prescription medications deprescribed, and 57% of patients were started on memory-related medications. A total of 712 medications (p-value 0.001) were deprescribed, with 510 prescriptions and 202 non-prescription items. Out of the 712 deprescribed drugs, 374 were discontinued with no therapeutic substitutions, 202 were reduced in dosage and 136 were switched to a safer alternative. A total of 43 patients showed improved Activities of Daily Living (ADL) performance after 3 and 6 months.

* Corresponding address: Clinical Pharmacy, Winchester District Memorial Hospital, 56 Louise Street, Winchester, ON, K0K0C0, Canada.
E-mail: Elbeddini.a@gmail.com (A. Elbeddini)

Peer review under responsibility of Taibah University.
Introduction

Dementia is a syndrome that affects many facets of cognitive function including memory, learning, and thinking. Alzheimer’s disease (AD), the most common cause of dementia, is a neurodegenerative brain disease primarily seen in the elderly population. As the sixth leading cause of death in the United States, AD is associated with significant disability and morbidity. The average lifetime cost of care for patients with dementia was $357,297 in 2019. The neurological changes leading to AD start about 20 years before symptoms are observed. The pathology and aetiology of AD lack clarity. However, the accumulation of beta-amyloid plaques outside the neurons and the presence of tau tangles inside neurons have been reported in AD patients, ultimately hindering neuronal communication and reducing cognitive function.

Diagnosis of AD typically involves collecting comprehensive patient history, including changes in behaviour and cognition, psychiatric history, medication use, caregivers’ and family members’ perspective of patient’s behaviour, cognitive testing, and neurological and physical examinations. In some circumstances, a positron emission tomography (PET) scan of the brain and a lumbar puncture to find beta-amyloid plaques and tau tangles in cerebrospinal fluid are also used for diagnosis.

Cognitive changes may be a result of age, genetics, sex, medications, comorbidities, diet, physical activity, smoking, and alcohol use. Risk factors such as medications and social history are modifiable, however, some of the damage to brain function might have accumulated over the patient’s lifetime and cannot be reversed. The temporary effect of drugs on attention, memory, language, and executive and cognitive functions are often reversible upon discontinuation or tapering of drugs. Therefore, many elderly patients are suitable candidates for deprescribing programmes. Deprescribing is the supervised process of tapering down doses or discontinuing drugs when the risk of side effects outweighs the benefits. The goal is to minimise harm while simultaneously improving patient health outcomes, by identifying potentially inappropriate medications (PIM). Different tools can be used for identifying PIMs, including The Beers Criteria, Screening Tool for Older People’s Prescriptions (STOPP), and the Medication Appropriateness Index. However, all manifestations of memory impairment are not signs of AD. Other causes of memory impairment can be mild cognitive impairment, forgetfulness due to ageing, emotional problems, or different types of dementia. Mild cognitive impairment (MCI) is seen in 15-20% of adults aged above 65 years. MCI is considered an early sign of dementia, although not all patients with MCI develop dementia later in life.

There are currently no pharmacological treatments for altering the progression of dementia or its damage to the neurons. The U.S. Food and Drug Administration (FDA) has approved treatments that temporarily improve cognitive symptoms through altering the brain neurotransmitters; however, the extent and the duration of efficacy are limited. Cholinesterase inhibitors (ChEIs) are the mainstay of treatment for cognitive and functional symptoms of AD and may help manage behavioural and psychological symptoms in mild to moderate dementia. There is no evidence for the superiority of one agent; however, donepezil is usually better tolerated by patients compared to both galantamine and rivastigmine. The DOMINO-AD (Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease) trial in patients with moderate to severe AD taking donepezil showed there was a benefit in continuing donepezil or starting memantine if the former was discontinued. Memantine has demonstrated a small clinical benefit on cognition, activities of daily living (ADLs), behaviour, and mood. It is given with donepezil; however, there is a lack of evidence on the mechanism of their synergistic activity. For those who cannot tolerate ChEIs, memantine monotherapy is considered. The cost of these drugs is covered under Ontario’s public drug plan, under the condition that the patient’s cognitive test results meet a certain coverage criteria. However, cognitive test results are poor indicators of memory function.

Although the cost-effectiveness of these agents has historically been a barrier to treatment, this has become less of an issue with the introduction of lower-cost generic alternatives and the emergence of better efficacy data. There is no cost-effective evidence on the combination of donepezil and memantine.
To address gaps in care for those living with memory impairments, such as dementia in an ageing population, Dr. Lee and her team from Ontario created MINT Memory Clinics. The main focus of memory clinics was to create an environment that facilitates specialised and multidisciplinary team-based approaches to address patients’ concerns and promote accessibility to equitable healthcare, especially for those who may be underserved due to physical location or those who lack a primary physician. As of today, MINT (Multi-specialty Interprofessional Team-Based) Memory Clinics have established 110 different clinics across Ontario, Canada, many of which are in rural or remote communities. Of these, Nation River Memory Clinic, which serves patients in a rural area of the Ottawa district, is the focus in this study. The clinic runs for 8 h each month, focusing on four patients at a time to provide a patient-centred service that empowers them through education on medication efficacy and safety. Furthermore, the clinic team assesses the presence of potentially inappropriate medications that may be contributing to memory loss, cognitive impairment, and increased risk of falls to the elderly. Patients can contact team members for any concerns outside of clinic days, which reduces the difficulties that patients in remote areas usually face when accessing care. Memory clinics aim to stop the progression of memory decline by addressing diverse contributing factors, such as medications, living environment, and comorbidities.

The clinic’s primary goal is to provide quality care that helps patients cope with their medical conditions and increase independence in performing functional activities. By creating an environment that facilitates interprofessional care, a multidisciplinary approach can be taken to create a care plan for patients to manage geriatric syndromes, such as cognitive decline. Other activities include preventing harm to patients or the public on the roads, by informing the Ministry of Transportation about the patient’s condition, or collaborating with other institutions such as long-term care homes, hospitals, or other memory clinics, to ensure continuity of care.

The clinic’s multidisciplinary team includes two physicians, two nurses, a pharmacist, a medical resident, an Alzheimer’s specialist, and a social worker, who are trained in geriatric care. The clinic accepts patients with impaired memory function referred by their family physician, and the hospital also provides financial and medical resources and referrals. Team members meet a week before the clinic day to review patient case and assess their medical history, medications, lab results, cognitive assessments, and medical imaging and radiology results. Following patient examination, the clinic team meets again during the clinic day to create a care plan.

The primary objective of this study is to evaluate the role of a specialised and multidisciplinary healthcare team in a memory clinic and their contributions in providing care and managing patients suffering from MCI and dementia. There is a special focus on the role of the pharmacist and the medication management contributions, such as deprescribing. Using the results of the study, we hope to improve the quality of care provided to this patient population, decrease the progression of dementia, and support the families involved in the process.

Materials and Methods

Memory clinic data collection

This study obtained the dataset for the geriatric and memory clinic in a rural area in Ontario, Canada, from 102 patients between January 2017 to January 2019. The clinic runs once a month for 8 h, in which four patients are examined and cared for. On two occasions, an additional patient was added to the clinic day due to an urgent impromptu physician referral. Patient cases are reviewed a week before the clinic day and discussed among the multidisciplinary team. We excluded alcohol dementia, post-anaesthetic memory impairment, post-traumatic memory impairment, and unclear diagnoses. We included patients with MCI and specific dementia subtypes including frontotemporal lobar dementia (FTLD), Parkinson’s disease dementia (PDD), mixed dementia (MD), vascular dementia (VD), AD, and Lewy body dementia (LBD). The data were analysed using Stata Data Analysis software. T-test was used to calculate the p-values and confidence intervals.

Patient assessment

During the patient’s visit, further testing and examinations are performed to make accurate assessments and plans. After conducting the tests and speaking to the patient and caregivers, the team of healthcare professionals meets to discuss each case. By the end of the appointment, the patient receives a comprehensive care plan and education on medication management, ADL management, available resources, and follow-up plans. The care plan is communicated to the patient’s primary care provider, who will manage and monitor the patient’s medication changes and inform the original prescriber about any discontinued medications. Additionally, the patient or caregiver is instructed to self-monitor for any adverse effects or changes in their comorbid condition during the prescribing process and to report any changes to us or their primary care provider. The patient may receive instructions on avoiding operating heavy machinery and the start of blister packaging to improve their compliance and adherence.

Cognitive function testing

The relevant laboratory and radiological results are obtained in advance, and a thorough patient history is taken during the appointment. Patients fill the Functional Activities Questionnaire (FAQ) and Lawton and Brody’s Activity of Daily Living (ADL) to determine the impact of
cognitive impairment in completing daily tasks. The patients’ cognitive functions are assessed using different tools in the following order: Brain Maps, Montreal Cognitive Assessment (MoCA), Pentagons, Trail Testing and CLOX (clock drawing test), Animal list generation, Executive Function Test, Cornell Scale for Depression in Dementia, gait and neurological assessment. Other miscellaneous tests that may be conducted are MoCA version 2 and version 3, Frontal Behavioural Inventory (FBI), gait quality, praxis, and physical exam. The descriptions of these tests are included in Table 2. The test findings are documented, interpreted, reviewed by the entire team and shared with the patient, caregiver, and primary physician.

**Role of pharmacists in medication management**

The week before the memory clinic, the pharmacist looks into multiple sources of information to collect a Best Possible Medication History (BPMH) which includes obtaining community pharmacy records, looking up electronic health records, calling family members, and contacting the family physician’s office. The pharmacist will then perform medication reconciliation and verify the appropriateness of therapy through assessing doses based on liver and kidney function, indication, and safety. Pharmacists consider geriatric syndromes, such as frailty, dehydration, and confusion, as well as assess potential areas of deprescribing, to improve cognition and reduce undesired side effects. The pharmacist may also choose to reach out to specialists for consultation.

When the patient visits the clinic, the pharmacist reviews their medications with the patient, family members, and caregivers to make sure there are no discrepancies. The pharmacist must also verify if the patient is taking any herbs, supplements, vitamins, and over-the-counter medications. During their session, the pharmacist assesses the patient’s medication adherence and addresses any side effects or medication-related questions. Patients are also educated on five questions to ask their physicians about their medications, which are summarised in a handout. These questions address changes to the patient’s medication, proper use of drugs, monitoring for efficacy, drug side effects and followup procedures. Through these questions, patients can become more involved in their care and gain a better understanding of their medication regimen. By the end of the session, the pharmacist contacts the patient’s community pharmacy to discuss ways to improve patient medication compliance, such as the preparation of medication in blister packages.

**Follow-up plan**

Based on the outcome of the first visit, the patient is followed up in 3, 6, or 12 months. Depending on the patient case, they may also be referred to a specialist. The social worker plays a critical role in home or nursing home safety assessment as well as offering resources and support groups. During the follow-up, the memory clinic team typically monitors the progression of diseases, any improvement of symptoms, adherence to medications, and side effect management. Memory enhancers may be discontinued if the risks outweigh the benefits and if there is no improvement following a year of administration. Other follow-up assessments include ensuring the patient is demonstrating good compliance with medications, as well as ensuring that patients have not been driving or operating heavy machinery against the physician’s advice.

**Results**

**Patient demographics**

Based on the data in Table 3, the patients’ median age was 67, and almost all were above 65 years. Most of the patients were married males, aged 65–74 years. About 86% were retired and about 90% did not have a university or college degree. The majority of patients had vascular, frontotemporal, and Alzheimer’s dementia, together forming more than 80% of the cases. Patients with MCI formed a minority of the cases, with only 5 out of 102 cases. Most patients had an average of seven different comorbid medical conditions (see Figures 1–6).

**Pharmacy services at the memory clinic**

Most patients had an average of 5 prescription and 2 non-prescription medications deprescribed, and 57% of the patients were started on memory-related medications. A total of 712 medications (p-value of 0.001) were deprescribed, with 510 prescription and 202 non-prescription items. Out of the 712 deprescribed drugs, 374 were discontinued with no therapeutic substitution, 202 were reduced in dosage and 136 were switched to a safer alternative. Antidepressants and opioids were the most common drugs to be deprescribed, forming 31% and 18% of prescription medication deprescribing, respectively. These were followed by benzodiazepines and anticholinergics. The data includes drugs that were reduced in dose, switched to a safer alternative, or discontinued altogether with no alternative given. 58 patients were started on memory enhancers, and 13 were referred to a specialist.

**Follow-up outcomes**

A total of 43 patients showed improved ADL performance after 3 and 6 months and 68 patients showed improvement after 12 months. At a three-month follow-up, 32 patients were experiencing common side effects from memory enhancers such as nausea, vomiting, and headaches. This number decreased to 26 and 14 after six and 12 months, respectively. In the first three months, only five patients had their memory enhancers discontinued due to intolerance and seven patients had their memory enhancers discontinued after a year of no
Table 1: FDA-approved drugs for dementia.

| Drug Name       | Mechanism of Action                          | Dose                          | Onset    | Side effects                        | Cost ($)  | Place in Therapy                  |
|-----------------|----------------------------------------------|-------------------------------|----------|-------------------------------------|-----------|-----------------------------------|
| Memantine       | Non-competitive NMDA antagonist               | Initial: 5 mg daily           | 1–3 months | Dizziness, headache, confusion, nausea, and vomiting | $30-60    | Alzheimer’s dementia              |
|                 |                                              | Target: 10 mg twice daily     |          |                                     |           |                                   |
| Donepezil       | Reversible non-competitive acetylcholinesterase inhibitor | Initial: 5 mg daily           | 12–24 weeks | Nausea and vomiting, bradycardia, headache, anorexia, weight loss, diarrhoea | <$30     | Lewy Body, Parkinson’s, Alzheimer’s dementia, mixed vascular dementia (VD) and AD |
|                 |                                              | Target: 10 mg daily           |          |                                     |           |                                   |
| Galantamine     | Reversible, competitive acetylcholinesterase inhibitor and modulator of nicotinic acetylcholine receptor | Initial: 8 mg daily           | 1–3 months | Nausea and vomiting, bradycardia, headache, anorexia, weight loss, diarrhoea | Oral $30-60 Transdermal patch $90-120 | Alzheimer’s dementia, mixed VD and AD, Mild to moderate Lewy body dementia if rivastigmine and donepezil are not tolerated |
| Rivastigmine    | Acetylcholinesterase inhibitor and butyryl cholinesterase inhibitor | Initial: 1.5 mg twice daily   | 1–3 months | Nausea and vomiting, bradycardia, headache, anorexia, weight loss, diarrhoea | $30-60    | Lewy Body, Parkinson’s, Alzheimer’s dementia, mixed VD and AD                  |
|                 |                                              | Target: 6–12 mg daily divided in 2–3 doses |          |                                     |           |                                   |

<sup>a</sup> Cost of a 30-day supply of target or usual dose in Canadian dollars.

Table 2: Examination processes for patients, parameters tested, and analysis of the test results.

| Test Name                                           | Parameters Assessed                                                                 | Result Analysis                                                                 |
|-----------------------------------------------------|------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Activities of Daily Living (ADLs)                   | 1. Basic (Dressing, Eating, Ambulation, Toileting, Hygiene)                         | Observing changes from a normal baseline (yes/no)                              |
|                                                     | 2. Instrumental (Shopping, Housework/hobby, Accounting/banking/bills/taxes, Food preparation, telephone/tools/transportation) |                                                                                  |
| Functional Activities Questionnaire (FAQ)           | 3. Writing cheques and paying bills                                               | Total score out of 30                                                           |
|                                                     | 4. Business affairs and tax assembling                                            |                                                                                  |
|                                                     | 5. Shopping for clothes and groceries                                            |                                                                                  |
|                                                     | 6. Playing games or working on a hobby                                            |                                                                                  |
|                                                     | 7. Heating water and using stove                                                 |                                                                                  |
|                                                     | 8. Preparing meals                                                               |                                                                                  |
|                                                     | 9. Keeping track of current events                                               |                                                                                  |
|                                                     | 10. Paying attention to and understanding movies, TV shows, books                |                                                                                  |
|                                                     | 11. Remembering appointments and family occasions                                |                                                                                  |
|                                                     | 12. Travelling outside the neighbourhood, taking buses                            |                                                                                  |
| Executive Function and Praxis                       | 1. Months of the year backwards                                                  | Impaired vs intact and scoring using the number of errors                      |
|                                                     | 2. Go-no-go                                                                     |                                                                                  |
|                                                     | 3. Luria                                                                        |                                                                                  |
|                                                     | 4. Pantomime tool use                                                            |                                                                                  |
|                                                     | 5. Gestures                                                                      |                                                                                  |
|                                                     | 6. Bucco facial                                                                 |                                                                                  |
| Cornell Scale for Depression in Dementia            | 7. Mood-related signs                                                            | A score of >10/38 is probable and a score of >18/38 indicates definite major depressive episode |
|                                                     | 8. Behavioural disturbances                                                      |                                                                                  |
|                                                     | 9. Physical signs                                                                |                                                                                  |
|                                                     | 10. Cyclic functions                                                             |                                                                                  |
|                                                     | 11. Ideational disturbances                                                      |                                                                                  |
| Montreal Cognitive Assessment (MoCA)                 | 1. Visuospatial/executive                                                        | The average MoCA score for MCI is 22/30 (range 19–25) and for Mild AD is 16/30 (11–21). The cut-off to distinguish between MCI and AD is 18/30 |
|                                                     | 2. Naming                                                                       |                                                                                  |
|                                                     | 3. Memory                                                                       |                                                                                  |
|                                                     | 4. Attention                                                                     |                                                                                  |
|                                                     | 5. Language                                                                      |                                                                                  |
|                                                     | 6. Abstraction                                                                   |                                                                                  |
|                                                     | 7. Delayed recall                                                                |                                                                                  |
|                                                     | 8. Orientation                                                                  |                                                                                  |
Table 2 (continued)

| Test Name                    | Parameters Assessed                                                                 | Result Analysis                                                                 |
|------------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Animal list generation       | 1. 15 sec                                                                            | Count the number recalled in these timeframes. Less than 11 to 13 is below normal limits |
|                              | 2. 30 sec                                                                            |                                                                                  |
|                              | 3. 45 sec                                                                            |                                                                                  |
|                              | 4. 60 sec                                                                            |                                                                                  |
| Trail A and B                | 5. Record the time it takes for the patient to connect numbered dots/circles         | Impaired vs intact                                                               |
| CLOX 1 and 2                 | 6. Patient to draw a clock and show 1:45                                             | Impaired vs intact                                                               |
|                              | 7. Assess for number ordering, spacing, hour and minute hands, and correct orientation of hands |                                                                                  |
| Frontal Behavioural          | 8. Negative behaviour (Apathy, aspontaneity, indiffERENCE, inflexibility, disorganisation, inattention, personal neglect, loss of insight, logopenic, aphasis, comprehension deficit, apraxia) | >30/72 is frontotemporal dementia                                                 |
| Inventory (FBI)              | 9. Step length                                                                      | Used to assess for ataxic, parkinsonian, hemiparetic, frontal, neuropathic or spastic gaits |
|                              | 10. Step width                                                                       |                                                                                  |
|                              | 11. Step height                                                                      |                                                                                  |
|                              | 12. Hip/pelvis                                                                       |                                                                                  |
|                              | 13. Symmetry                                                                         |                                                                                  |
| Gait Assessment              | 14. Parkinsonism                                                                     | Refer cognitively-impaired patients to specialists if unexplained neurological findings or Parkinsonism |
|                              | 15. Asterix                                                                          |                                                                                  |
|                              | 16. Cerebellar findings                                                              |                                                                                  |
|                              | 17. Ideomotor apraxia                                                                |                                                                                  |
|                              | 18. Rhomberg                                                                         |                                                                                  |

Table 3: Patient characteristics.

| Variable                     | (n = 102) p-value |       |
|------------------------------|--------------------|-------|
| Mean age (years)             | 67 0.909           |       |
| Age category                 | 54 years and below | 0 0.000 |
|                              | 55–64 years        | 1 0.748 |
|                              | 65–74 years        | 59 0.500 |
|                              | 75 years and above | 42 0.500 |
| Gender                       | Male 63 0.090      |       |
|                              | Female 39 0.251    |       |
| Marital status               | Married 77 0.900   |       |
|                              | Divorced/widowed   | 11 0.000 |
|                              | Single 14 0.251    |       |
| Employment status            | Employed/Self-employed | 13 0.090 |
|                              | Unemployed 2 0.500 |       |
|                              | Retired 87 0.909   |       |
| Education                    | Primary school 34 0.251 |     |
|                              | Lower secondary school | 6 0.748 |
|                              | Upper secondary school | 50 0.041 |
|                              | Tertiary education 12 0.999 |     |
| Average number of comorbidities per patient | 7 1.120 |     |

Figure 1: Common causes of dementia.
improvement in dementia symptoms. About 80% of the patients were adherent to their blister packs in the first 3 and 6 months post-visit, but this number decreased to 68% by 12 months.

Factors Contributing to Cognitive Impairment

- Aging
- Social history
- Malnutrition
- Medical conditions
- Medications
- Emotional problems

Neurodegeneration

- Poor diet
- Deficiency of vitamin B12
- Deficiency of minerals
- Brain tumours, infection, or blood clots
- Thyroid, liver and kidney issues
- Head trauma
- Anticholinergics and antihistamines
- Chemotherapy
- Cardiovascular medications
- Corticosteroids
- Sedatives (BDZ and non-BDZ) and opioids
- Antipsychotics, antidepressants
- Antiparkinsonian and anticonvulsants
- Stress and anxiety
- Depression
- Traumatic life changes
- Malnutrition
- Deficiency of minerals
- Brain tumours, infection, or blood clots
- Thyroid, liver and kidney issues
- Head trauma
- Anticholinergics and antihistamines
- Chemotherapy
- Cardiovascular medications
- Corticosteroids
- Sedatives (BDZ and non-BDZ) and opioids
- Antipsychotics, antidepressants
- Antiparkinsonian and anticonvulsants
- Stress and anxiety
- Depression
- Traumatic life changes

Figure 2: Risk factors associated with cognitive impairment.2-5

Figure 3: Alzheimer's disease neurodegeneration continuum.2

Preclinical AD: No symptoms
MCI due to AD: Very mild symptoms that do not interfere with daily activities
Mild AD: Symptoms interfere with some daily activities
Moderate AD: Symptoms interfere with many daily activities
Severe AD: Symptoms interfere with most daily activities

Figure 4: Services offered at the memory clinic that can positively impact dementia patients' health outcomes.

Patient Assessment

- Clinic Day: Cognitive tests are conducted and outcomes are discussed by the team to create a care plan and a follow-up plan for each patient. The outcome of the team meeting is discussed with the patient and caregivers.
- One week before: The multidisciplinary team meets to discuss the medical history of the patients to mark missing or conflicting data and learn more about the patient history and what to expect during the visit.

Figure 5: Steps involved in patient assessment at the memory clinic.

improvement in dementia symptoms. About 80% of the patients were adherent to their blister packs in the first 3 and 6 months post-visit, but this number decreased to 68% by 12 months.
Family physician refers patients to the memory clinic based on the patient or family members’ concerns related to memory loss.

The appointment is made and patient is mailed a preparation package: FAQ forms and medical history forms to be filled prior to the appointment at the clinic.

Pharmacist: One week before: Collects BPMH, medication reconciliation, assesses the appropriateness of the medication and the dose, looks at lab values and exam results, reads physician’s notes, and discusses with specialists. On the day of clinic: Reviews all medications and verifies the indications, adherence and side effects, counsels and answers questions about medication use.

Social worker: Conducts Cornell test for patient to screen for depression in dementia, Cornell, Zarit and FBI testing for family members or caregivers to assess the burden on family members, burnouts, and need for home safety assessment.

Nurse: Reviews patient’s forms and asks for further details on patient history, if necessary. Conducts pentagons, MoCA, Trail Testing and CLOX, Animal list generation, Executive Function Test if history suggests executive dysfunction.

Team Discussion: The team, including physicians, review the results of the tests and create a management plan. The outcome of the assessment and plans is sent to the referring physicians.

Team meets the patient and the family members to discuss the management plan and the need for further testing or assessment. Comprehensive report is generated to be shared on patient’s electronic health records.

Follow-up plan: Based on the outcomes of the first visit and resources available to patients, follow ups will be at 3, 6, or 12 months to monitor the progression of diseases, any improvement in symptoms and for any side effects. Memory enhancers are discontinued if the risk outweighs benefit and there is no improvement in a year. The patients will be referred to a specialist if needed. Role of the social worker is critical in home or nursing home safety assessment and offering resources and support groups.

Figure 6: Summary of the steps and professionals involved in patient referral to the clinic, patient and caregiver assessments, care plan generation, patient counselling, and follow-up.

Table 4: Classification of diagnosis.

| Diagnosis    | N = 102 | Average age | p-value | 95% confidence interval |
|--------------|---------|-------------|---------|-------------------------|
| MCI          | 5       | 68          | 0.6611  | 0.49-0.86               |
| FTLD         | 22      | 78          | 0.8206  | 0.71-0.84               |
| VD           | 35      | 82          | 0.7753  | 0.76-0.87               |
| PDD          | 5       | 73          | 0.6611  | 0.54-0.91               |
| LBD          | 8       | 68          | 0.7054  | 0.55-0.80               |
| Mixed dementia | 8      | 65          | 0.5000  | 0.52-0.77               |
| AD           | 19      | 78          | 0.8026  | 0.70-0.85               |

Table 5: Medication changes and other services performed at the clinic.

| Parameter                                               | Value | p-value | 95% confidence interval |
|---------------------------------------------------------|-------|---------|-------------------------|
| Total number of drugs deprescribed                      | 712   | 0.001   | 0.53-0.64               |
| Total number of discontinued drugs                      | 374   | 0.002   | 0.65-0.78               |
| Total number of drugs switched to a safer alternative   | 136   | 0.054   | 0.92-1.1                |
| Total number of drugs reduced in dose                   | 202   | 0.005   | 0.32-0.40               |
| Total number of patients prescribed memory enhancers    | 58    | 0.007   | 0.50-0.64               |
| Total number of patients referred to a specialist        | 13    | 0.041   | 0.55-0.60               |
### Table 6: Medication changes per patient.

| Parameter                                      | (n = 102) | p-value | 95% confidence interval |
|-----------------------------------------------|-----------|---------|-------------------------|
| Average number of prescription drugs deprescribed per patient | 5         | 0.009   | 0.20-0.79               |
| Average number of non-prescription drugs deprescribed per patient | 2         | 0.002   | 0.94-1.49               |
| Average number of medications deprescribed per patient | 7         | 0.004   | 0.21-0.39               |
| Average number of medications introduced as safer substitute per patient | 2         | 0.251   | 0.94-1.49               |

### Table 7: Medication deprescribed sorted by pharmacological categories.

| Drug Class               | Total deprescribed | Dose reduced | Discontinued | Safer alternative chosen | p-value |
|--------------------------|--------------------|--------------|--------------|--------------------------|---------|
| Antidepressants          | 154                | 49           | 81           | 24                       | 0.079   |
| Antipsychotics           | 54                 | 11           | 29           | 14                       | 0.165   |
| Anticholinergics         | 72                 | 3            | 53           | 16                       | 0.011   |
| Antihistamines           | 54                 | 8            | 31           | 15                       | 0.120   |
| Anti-emetics             | 14                 | 0            | 4            | 10                       | 1.030   |
| Benzodiazepines/Z-drugs  | 69                 | 51           | 6            | 12                       | 0.010   |
| Opioids                  | 93                 | 24           | 39           | 30                       | 0.050   |
| OTC/herbals              | 202                | 56           | 131          | 15                       | 0.002   |

### Table 8: Follow-up outcomes.

| Parameter                                      | 3 months | 6 months | 1 year |
|-----------------------------------------------|----------|----------|--------|
| Total number of patients at follow-ups        | 45       | 50       | 70     |
| Total number of patients with positive experience | 45 (100%) | 50 (100%) | 55 (79%) |
| Total number of patients with improved physical abilities and independence | 43 (96%) | 43 (86%) | 67 (96%) |
| Total number of patients experiencing common side-effects from memory enhancers | 32 (71%) | 24 (48%) | 14 (20%) |
| 50. Nausea and vomiting                       | 26 (58%) | 20 (40%) | 13 (19%) |
| 51. Headache                                  | 5 (11.1%) | 3 (6%)   | 0 (0%)  |
| 52. Weight loss                               | 1 (2.2%)  | 1 (2%)   | 1 (1.4%) |
| Number of patients who stopped memory enhancers due to intolerability | 5 (11.1%) | 0 (0%)   | 0 (0%)  |
| Number of patients being deprescribed memory enhancers due to lack of efficacy | 0 (0%)   | 0 (0%)   | 7 (10%) |

### Table 9: Summary of additional literature.

| Author                        | Objectives                                                                 | Design                        | Sample                                         | Country | Summary of Results                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|-------------------------------|------------------------------------------------|---------|-------------------------------------------------------------------------------------|
| Meeuwsen et al., 2012         | Compare the effectiveness of the treatment and coordination of care following the dementia diagnosis in memory clinics compared to general practitioners. | Randomised controlled trial   | Patients newly diagnosed with mild to moderate dementia living in the community (n = 175) | Netherlands | No evidence demonstrating that the treatment and coordination of care in memory clinics is superior to general practitioners following dementia diagnosis. |
| Gustafsson et al., 2017       | Assess the effect of comprehensive medication reviews performed by pharmacists that are part of a multidisciplinary team on drug-related hospital readmission rates among patients with dementia or cognitive impairment. | Randomised controlled trial   | Patients ≥65 years with dementia or cognitive impairment admitted to three wards at two hospitals in Sweden (n = 460) | Sweden   | Comprehensive medication reviews conducted by pharmacists significantly reduced the risk of drug-related hospital readmissions (HR = 0.49, 95% CI: 0.27–0.90). |
| Author                  | Objectives                                                                 | Design                                      | Sample                                                                 | Country   | Summary of Results                                                                 |
|------------------------|----------------------------------------------------------------------------|---------------------------------------------|----------------------------------------------------------------------|-----------|-----------------------------------------------------------------------------------|
| Elliott et al., 2010<sup>41</sup> | Measure the occurrence of drug-related problems (DRPs) in aged care and memory clinic patients and assess the potential role of a pharmacist in the resolution of these problems. | Interviews, DRPs rated by independent expert panel using validated criteria | Aged care and memory clinic patients at a tertiary care hospital (n = 46) | Australia | 113 total DRPs were identified by the pharmacist. Of the, 33% were not found in the medical record and 35% were rated by the expert panel as high or extreme risk. Pharmacist involvement resulted in more comprehensive medication histories and an increased rate of identifying unresolved DRPs. |
| Cross et al., 2017<sup>42</sup> | Assess the association between PIM and anticholinergic cognitive burden to mortality in older patients attending memory clinics | Cross-sectional and longitudinal analysis | Patients living in the community attending nine memory clinics with mild cognitive impairment or dementia (n = 964) | Australia | Potentially inappropriate medications (HR = 1.42, 95% CI: 1.12–1.80) and higher anticholinergic cognitive burden (HR = 1.18, 95% CI: 1.06–1.32) was associated with mortality. General consensus of online posts called for the holistic care of dementia patients that involves not only an interprofessional team of health and social care practitioners but family members and patients. Three types of barriers were identified: Patient, provider, and system related. Barriers of note include: patient non-adherence to management plans, lack of time during consultations, and lack of support services. |
| Robertshaw et al., 2017<sup>43</sup> | Understand the views of caregivers, family members, and health care professionals on integrated health and social care for dementia. | Framework analysis of qualitative data | Online discussion posts of caregivers, family members and healthcare professionals in the “Bridging the Dementia Divide”, online course at the University of Derby (n = 847) | UK        |                                                                                   |
| Mansfield et al., 2018<sup>44</sup> | Understand the perspective of primary care providers on the barriers in providing optimised care for dementia patients. | Review of quantitative studies | Studies rated as "moderate" or "strong" in terms of methodological quality based on rating criteria for quantitative studies (n = 16) | US        |                                                                                   |
| Rousseau et al., 2019<sup>45</sup> | Measure the efficacy of a specialised, interprofessional care unit in reducing severe BPSD | Retrospective chart review | Patients with severe BPSD symptoms are a part of the specialised interprofessional care unit admitted at IUSMQ in Quebec City (n = 54) | Canada     | Neuropsychiatric inventory (NPI) was significantly reduced at discharge compared to at admission (p = <0.001, 95% CI: −13.30 to −4.99)                                                                 |

(continued on next page)
Discussion

Data analysis

This study highlights some important differences observed in the demographics of dementia patients. Based on statistics by the Government of Canada, the prevalence of dementia is highest among female patients older than 85 years. Most dementia patients attended university or college. However, a majority of male patients aged between 65 and 74 years were retired and did not attend post-secondary school. Another demographic discrepancy is that the most common type of dementia in Canada is AD, but this study indicates it as VD. The difference in these demographics of the patients in this clinic can be attributed to the clinic’s geographic rural setting.

From the results, it is evident that the memory clinic had a significant effect on patients’ drug regimens. A total of 712 drugs from the Beers Criteria of inappropriate medicines for the elderly were deprescribed from 2017 to 2019. On average, each patient had five prescription and two non-prescription medications deprescribed. More than half of the patients were found to be candidates for starting memory medications, and 13 were referred to specialists. Some patients had their memory enhancers discontinued after a while due to intolerance or inefficacy.

Significance of medication optimisation in memory clinics

An increasing number of Canadians are living with dementia, with currently half a million people with an official diagnosis. The mortality rate is about 75 per 1,000 patients aged between 65 and 69 years and 207 per 1000 patients for those above 85 years. The numbers are expected to reach 937,000 cases, and the associated cost to be $16.6 billion in 2031. The cost of care for these patients currently is about $10.4 billion, which burdens the healthcare system and patient caregivers. Given that more than half the patients are facing struggles regarding access to care and support, investing in a care system that helps them increase their independence by improving their cognitive and functional abilities, will enhance their quality of life, life expectancy, and psychological well-being. The memory clinics in Canada aim to increase the primary care practice’s capacity to assess and manage patients dealing with cognitive impairment.

In this retrospective study, we demonstrate the services provided at a memory clinic in a rural area of Canada. The results of this study highlight the role of pharmacists in medication optimisation and improved patient outcomes. Their role in caring for dementia patients extends beyond the assessment of memory enhancer appropriateness. Pharmacists are medication experts who take a holistic approach in assessing medications and addressing safety concerns, adherence issues, cost burdens, and comorbidities.

The safety and tolerability of all the medications of the patient impact their cognitive and overall well-being. Most patients in this clinic were deprescribed an average of seven medications, highlighting the importance of medication management in this population. Polypharmacy, which is defined as being on five or more chronic medications, is common among the elderly and puts patients at a higher risk of memory impairment, as it is likely that they are on one or more problematic medications. For instance, anticholinergics are associated with undesired side effects in the elderly including urinary retention, constipation, and dry mouth. At the neurological level, they cause confusion, memory impairment, delirium, and agitation. Other agents associated with falls and fractures in the elderly are also subjected to deprescribing.

The Beers criteria for inappropriate drug use in the elderly describes the list of potential agents that contribute to poorer outcomes in geriatric patients. Among the most common drug classes subjected to deprescribing in patients with dementia are the antipsychotics and antidepressants used for insomnia or behavioural and psychological symptoms.
Benzodiazepines need to be tapered by prescribers in the cause sedation, delirium, and memory impairment. They can cause insomnia and agitation in the elderly population. They can cause sedation, delirium, and memory impairment. Benzodiazepines need to be tapered by prescribers in the elderly, regardless of the duration of use. Opioids that are used for acute or chronic pain are highly sedative and cause brain fogginess and should be used at the lowest effective dose and for the shortest duration. Most doses can be tapered down to lower doses or be discontinued. Over-the-counter and self-care medications and herbals that may also be subjected to deprescribing include dextromethorphan, antihistamines, and Ginkgo Biloba. First-generation antihistamines and dextromethorphan with sedative and anticholinergic effects, which are used for cold and allergies or as a sleep aid (e.g. diphenhydramine), can cause cognition impairment. Ginkgo Biloba extract is used by the elderly to help with symptoms of dementia; however, evidence regarding its clinical benefit is inconsistent. Therefore, based on a lack of evidence of efficacy and potential interaction with other drugs, Ginkgo can be deprescribed in this population.

Drugs used in dementia are also candidates for deprescribing, if efficacy is not observed, cognition is significantly declined, or the patient is at end-stage AD after a year of taking the medication. Deprescribing memory medications is also recommended if the patient has other terminal illnesses, is not adherent to the medication, in cases of severe agitation, and potentially risky drug interactions. The dose is lowered every four weeks with close monitoring.

Elderly patients with dementia have low adherence to medications. The memory clinic’s follow-ups aim to flag any non-compliance to the medication regimen by collaborating with community pharmacists and tracking blister packs. Adherence to medications is particularly important in improving patient health outcomes including cognitive function, psychological well-being, and behaviour. Most of the patients in this study remained relatively compliant to their blister packages in the first three and six months; however, adherence levels decreased after 12 months. The pharmacist at the clinic addresses adherence issues by following up with the patient, maintaining electronic health records and communicating with the caregiver, family physician and community pharmacy. More than half of the patient population was started on memory enhancers based on the assessment criteria. Some had to discontinue the drug due to intolerance in the first three months, and only a few stopped taking it after a year of no improvement. This means that most patients who were prescribed memory enhancers benefited from their use and with the majority not experiencing major side effects. Deprescription of memory enhancers was based on an algorithm that assessed symptom improvement in these patients after a year of taking the medication, side effect tolerance, and other comorbidities.

Based on the survey results collected from the patients, 45 patients had a positive experience from their visit. They felt safer going home and felt empowered by the information provided to them about their medications. Based on the follow-up assessment, 65% of the patients had improved physical abilities and independence in performance by the end of the year, emphasizing the importance of the memory clinic in improving patient health outcomes.

**Literature review**

Memory clinics serve as an important setting for pharmacists to effectively collaborate with other healthcare professionals to improve dementia patient outcomes and also highlight the important role of pharmacists in an interprofessional team. A systematic review of existing literature studied the effectiveness of pharmacist-led interventions on the quality use of medications as well as the quality of life and health outcomes of those with cognitive impairment. This review re-inforces the benefits of proper medication-related services that may be provided by the healthcare team including medication reconciliation, reviews, and adherence, all of which have been shown to have beneficial health outcomes and cost savings. Other studies, one using semi-structured interviews and another using qualitative data, found comparable conclusions that highlight the importance of medication management of dementia patients; however, concerns were raised over the need for better interprofessional collaboration and care during transitions. By evaluating the services provided by memory clinics and pharmacists, this study demonstrates the added potential capabilities of pharmacists in the management of dementia patients in a multidisciplinary environment. A randomised control trial exploring the effectiveness of pharmacist interventions in the elderly with dementia had outcomes in which, deprescribing was the most common action in response to the identified drug-therapy problems, most of which were inappropriate drug usage and unnecessary drug therapy. For patients affected by dementia or memory deficits, deprescribing is an important aspect to address the side effects that unnecessary medications may have on memory and overall cognitive function. These are often reversible following its discontinuation or reduction in dose. A study conducted at Winchester hospital, Canada, followed 11 patients in a deprescribing pilot program that compared hospital admissions 6 months before and after deprescription. The majority of patients saw an improvement in cognitive function, higher alertness, and less confusion. With the successful implementation of a deprescribing programme and coordination with an interprofessional team, the potential positive impact pharmacists may have when caring for patients suffering from MCI or dementia can be observed. Further studies related to the importance of deprescribing and multidisciplinary models are highlighted in Table 4 (see Tables 5–9).

**Future directions for pharmacists**

Over the years, the role of a pharmacist has evolved and shifted away from solely a medication dispenser to a more clinical role engaged in patient medication management. There are limited studies with a primary focus on the clinical role of a pharmacist and more specifically, their role within an interprofessional team. With the development of their
role, it is important to provide supporting evidence from pharmacy practice research to assist in the discovery of new avenues that would allow for optimised patient care.\textsuperscript{47,50,51,53} More research is required to produce evidence-based guidelines and policies to support pharmacists and the multidisciplinary healthcare team, especially when caring for an older population suffering from MCI or dementia. Furthermore, higher quality research and implementation of more rigorous methodologies should be undertaken so that the literature may be gathered and systematically evaluated.\textsuperscript{54} Of the different designs, randomised control trials (RCTs) are one of the more robust methods of conducting research.\textsuperscript{55} A systematic review consisting of 54 different RCTs has been published that focuses on pharmaceutical care and medicine management. Although the overall amount of research is lacking, this review demonstrates the potential benefits of pharmacists and different pathways for research. Pharmaceutical care was shown to be effective in improving the short-term health outcomes for patients with a variety of comorbidities such as diabetes and other cardiovascular conditions. There is a need for future research to evaluate other disease states where data is lacking and to evaluate the persistence of the positive effects of pharmaceutical care beyond cessation of interventions in the long term.\textsuperscript{56} In our study, although medication compliance decreased from 80% in the first 3–6 months post-clinic visit to 68% after a year, patients still reported an increasing improvement in their physical abilities and independence as time from their visit progressed. It would be valuable to study the long-term clinical outcomes beyond one year and how pharmacists can tailor their care to retain long-term positive outcomes.

A multidisciplinary team allows for more effective collaboration between professions that can strengthen health systems and improve health outcomes.\textsuperscript{57} There is still a need for high-quality research in this area. Of 38 RCTs studying the clinical services provided by pharmacists working together with other specialties, positive outcomes were highest when interventions involved interprofessional collaboration and face-to-face verbal communication among team members.\textsuperscript{57} This knowledge, along with the significance of a pharmacist’s role within these teams, may be useful in determining how to provide efficient and effective care for patients suffering from dementia, as well as other comorbid diseases. Given that multiple healthcare providers in the patient’s circle of care were involved in this clinic, a key barrier in implementing this program was difficulty contacting healthcare providers in a timely manner, which contributed to delay in care. Strategies for more efficient communication within the circle of care needs to be explored. With more methodologically sound studies and sufficient patient follow-ups, the validity of these studies may be enhanced and would be valuable to explore in future research.

\textbf{Conclusion}

This study highlighted the role of memory clinics in increasing the capacity of primary care for managing dementia. The services provided in the memory clinic in this study included referrals to specialists, medication optimisation, cognitive testing, obtaining medical history, prescribing memory enhancers, offering follow-ups, and providing resources and support to caregivers. The findings of this study highlight the significant role of the pharmacist in medication optimisation for dementia patients. The limitations of this study included its retrospective nature, which lacked control and randomisation. In future studies, prospective studies with bigger sample sizes should be performed to confirm the significance of the results.

\textbf{Recommendations}

Based on our study, we recommend a multidisciplinary team approach in the context of memory clinics to optimise patient care for MCI or dementia. This approach allows for a thorough assessment of the patient, where drug-therapy problems are addressed upon discussion with the team and providing different perspectives in a holistic approach to care. The pharmacist has a vital role in ensuring medications are indicated, effective, safe, and appropriate which might otherwise be deprescribed to sustain better patient outcomes.

\textbf{Source of funding}

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

\textbf{Conflict of interest}

The authors have no conflict of interest to declare.

\textbf{Authors contributions}

AE worked on the original manuscript preparation, conceptualisation, data curation, analysis of the paper, literature search, data collection, and wrote, reviewed and edited the ideas. YT and JJV conducted research, provided research materials, and collected and organised data, and literature review. AEL analysed, interpreted data, conducted literature review, and edited the final draft. ZY assisted in writing initial and the final draft of article, and provided logistic support. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

\textbf{Acknowledgment}

We acknowledge the support from the administration team at the pharmacy and memory clinic in collecting data. We thank the pharmacy team for their endless support during the study. We also appreciate the work by the clinical informatics and medical record teams in assisting in the implementation and collecting relevant data.

\textbf{References}

1. Gale SA, Acar D, Daffner KR. Dementia [Internet] Am J Med 2018 Feb 6; 131(10): 1161–1169. Available from: https://doi.org/10.1016/j.amjmed.2018.01.022 [cited 2020 Jul 14].

2. 2020 Alzheimer’s disease facts and figures [Internet] Alzheimer’s Dementia 2020 Mar 1; 16(3): 391–460. Available from: https://
alz-journals-onlinelibrary-wiley.com/mvaccess.library.utoronto.ca/doi/full/10.1002/alz.12068 [cited 2020 Jul 4].

3. Edwards GA, Gámez N, Escobedo G, Calderon O, Moreno-Gonzalez I. Modifiable risk factors for Alzheimer’s disease. In: Frontiers in aging neuroscience, vol. 11. Frontiers Media S.A.; 2019.

4. Samuel MJ. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults [Internet]. J Am Geriatr Soc 2015 Nov 1; 63(11): 2227–2246. Available from: http://doidi.wiley.com/10.1111/jgs.13702 [cited 2020 Jul 4].

5. Ellison J. Drugs and medications that induce dementia-like symptoms [Internet]. BrightFocus Foundation; 2015. BrightFocus Foundation [cited 2020 Jul 4]. Available from: https://www.brightfocus.org/alzheimers/article/is-it-something-im-taking-medications-that-can-mimic-dementia.

6. O’Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: origin and progress [Internet]. Expert Rev Clin Pharmacol 2020 Jan 2; 13(1): 15–22 [cited 2020 Jul 8]. Available from: https://pubmed.ncbi.nlm.nih.gov/32100312/.

7. Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Edwards GA, Gamez N, Escobedo G, Calderon O, Moreno-Macol 1994 Aug 1; 175: 827–834. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7702254/.

8. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, et al. A summed score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994 Aug 1; 47(8): 891–896.

9. National Institute on Aging. Do memory problems always mean Alzheimer’s disease? National Institute on Aging; 2018 [Internet]. National Institute of Health (NIH). [cited 2020 Jun 15]. Available from: https://www.nia.nih.gov/health/do-memory-problems-always-mean-alzheimers-disease.

10. Bosma M, Nemirol F. Dementia. Compendium of therapeutic choices. 2019th ed. Canadian Pharmacists Association; 2019.

11. Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, Gauthier S, Patterson C, Chertkow H, Gordon M, Pfeffer RI, Kurosaki TT, Harrah CH, Chance MJM, Filos S. Measurement of functional activities in older adults in the community 1 [Internet] J Gerontol 1982; 37 [cited 2020 Jul 7]. Available from: https://academic.oup.com/gerontj/article-abstract/37/3/323/611005.

12. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontol 1969; 9(3): 179–186.

13. Institute for Safe Medication Practices. 5 questions to ask about your medications - ISMP Canada [Internet]. ISMP Canada; 2016 [cited 2020 Jul 4]. Available from: https://www.ismp-canada.org/medicare/ AskQuestions5Toolkit/.

14. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia [Internet]. Biol Psychiatry 1988 Feb 1; 23(3): 271–284 [cited 2020 Jul 8]. Available from: http://www.biologicalpsychiatryjournal.com/article/article/00063238/900388/fulltext.

15. Nasreddine Z. MoCA - montreal cognitive assessment [Internet]. MoCA; 2019 [cited 2020 Jul 4]. Available from: https://www.mocatest.org/.

16. Lee L, Loretta Hillier ab M, Paul Stolee C, Heckman G, Micheline Gagnon F, McAiney CA, et al. Enhancing dementia care: a primary care-based memory clinic; 2010.

17. Health Canada. Dementia in Canada, including Alzheimer’s disease highlights from the Canadian chronic disease surveillance system - Canada. ca [Internet]. Government of Canada; 2017 [cited 2020 Jul 11]. Available from: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/dementia-highlights-canadian-chronic-disease-surveillance.html.

18. Alzheimer Society of Canada. Alzheimer society 2017 awareness survey executive summary; 2017.

19. Regional Geriatric Program of Eastern Ontario. Centre for family medicine, memory clinic model [Internet]; 2020 [cited 2020 Jul 11]. Available from: http://www.rapoche.com/en/health-care-practitioners/primary-care/dementia-toolkit-for-primary-care-collaborative-shared-care-models/linda-lee.aspx; https://www.cochranelibrary.com/doi/10.1002/14651858.CD003120.pub3.full.

20. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia [Internet]. Biol Psychiatry 1988 Feb 1; 23(3): 271–284 [cited 2020 Jul 8]. Available from: http://www.biologicalpsychiatryjournal.com/article/article/00063238/900388/fulltext.

21. Lee L, Loretta Hillier ab M, Paul Stolee C, Heckman G, Micheline Gagnon F, McAiney CA, et al. Enhancing dementia care: a primary care-based memory clinic; 2010.

22. Health Canada. Dementia in Canada, including Alzheimer’s disease highlights from the Canadian chronic disease surveillance system - Canada. ca [Internet]. Government of Canada; 2017 [cited 2020 Jul 11]. Available from: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/dementia-highlights-canadian-chronic-disease-surveillance.html.

23. Alzheimer Society of Canada. Alzheimer society 2017 awareness survey executive summary; 2017.

24. Regional Geriatric Program of Eastern Ontario. Centre for family medicine, memory clinic model [Internet]; 2020 [cited 2020 Jul 11]. Available from: http://www.rapoche.com/en/health-care-practitioners/primary-care/dementia-toolkit-for-primary-care-collaborative-shared-care-models/linda-lee.aspx; https://www.cochranelibrary.com/doi/10.1002/14651858.CD003120.pub3.full.

25. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, et al. A summed score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994 Aug 1; 47(8): 891–896. Available from: http://www.rapoche.com/en/health-care-practitioners/primary-care/dementia-toolkit-for-primary-care-collaborative-shared-care-models/linda-lee.aspx; https://www.cochranelibrary.com/doi/10.1002/14651858.CD003120.pub3.full.

26. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, et al. A summed score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994 Aug 1; 47(8): 891–896. Available from: http://www.rapoche.com/en/health-care-practitioners/primary-care/dementia-toolkit-for-primary-care-collaborative-shared-care-models/linda-lee.aspx; https://www.cochranelibrary.com/doi/10.1002/14651858.CD003120.pub3.full.

27. Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: the downsizing strategy for polypharmacy in older people with dementia [Internet]. Int J Geriatr Psychiatry 2017; 32(12): 1205–1216 [cited 2020 Jul 10]. Available from: pmc/articles/PMC5724694/?report=abstract.

28. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial) [Internet]. Int J Geriatr Psychiatry 2017 Dec 1; 32(12): 1205–1216 [cited 2020 Jul 10]. Available from: pmc/articles/PMC5724694/?report=abstract.

29. Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicity [Internet] Curr Neuroparmacol 2013 Apr 25; 11(3): 315–335 [cited 2020 Jul 7]. Available from: pmc/articles/PMC3648782/?report=abstract.

30. Gauthier S, Patterson C, Chertkow H, Gordon M, Herrmann N, Rockwood K, et al. Recommendations of the 4th Canadian consensus conference on the diagnosis and treatment of dementia (CCCDTD4) [Internet] Can Geriatr J 2012 Dec 1; 15(4): 120–129 [cited 2020 Jul 8]. Available from: https://doi.org/10.5770/cjq.15.49.

31. Pfeffer RI, Kuroski TT, Harrah CH, Chance MJM, Filos S. Measurement of functional activities in older adults in the community 1 [Internet] J Gerontol 1982; 37 [cited 2020 Jul 7]. Available from: https://academic.oup.com/gerontj/article-abstract/37/3/323/611005.
33. Reeve E. Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine: recommendations developing organisations [Internet]; 2018 [cited 2020 Jul 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/28539102/.

34. Nguyen TA, Gilmartin-Thomas J, Tan ECK, Kalisch-Elliot L, Esthetic T, Gillam M, et al. The impact of pharmacist interventions on quality use of medicines, quality of life, and health outcomes in people with dementia and/or cognitive impairment: a systematic review [Internet]. J Alzheim Dis 2019; 71(1): 83–96 [cited 2020 Jul 14]. Available from: https://pubmed.ncbi.nlm.nih.gov/31356204/.

35. Deeks LS, Cooper GM, Draper B, Kurrle S, Gibson DM. Dementia, medication and transitions of care [Internet]. Res Soc Admin Pharm 2016; 12(3): 450–460 [cited 2020 Jul 14]. Available from: https://pubmed.ncbi.nlm.nih.gov/26265028/.

36. Maidment ID, Aston L, Moutela T, Fox CG, Hilton A. A qualitative study exploring medication management in people with dementia living in the community and the potential role of the community pharmacist [Internet]. Health Expect 2019; 20(5): 929–942 [cited 2020 Jul 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC600213/.

37. Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia [Internet]. BMC Pharmacology and Toxicology 2017; 18(1): 52 [cited 2020 Jul 14]. Available from: https://bmcpk.oxfordjournals.org/content/18/1/52.full.pdf.

38. Elbeddini A, Zhang C. The pharmacist’s role in successful deprescribing through hospital medication reconciliation [Internet]. Can Pharm J 2019; 152(3): 177–179 [cited 2020 Jul 15]. Available from: https://journals.sagepub.com/doi/10.1177/1715163518836136.

39. Meeuwsen EL, Melis RJ, Van Der Aa GCHM, Golleke-Willemsen GAM, De Leest BJM, Van Raak FHJM, et al. Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial [Internet] BMJ 2012; 344:e3086 [cited 2020 Jul 16]. Available from: https://www.bmj.com/content/344/bmj.e3086.

40. Gustafsson M, Sjolander M, Pfister B, Jonsson J, Schneede J, Löweim H. Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial [Internet]. Eur J Clin Pharmacol 2017; 73: 827–835 [cited 2020 Jul 16]. Available from: https://link.springer.com/article/10.1007/s00022-017-2249-8.

41. Elliott RA, Woodward MC. Medication-related problems in patients referred to aged care and memory care at a tertiary care hospital [Internet]. Australas J Ageing 2010. https://doi.org/10.1111/j.1741-6612.2010.00458.x [cited 2020 Jul 16]. Available from:

42. Cross AJ, Johnson G, Woodward MC, Ames D, Brodaty H, Wolfe R, et al. Potentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinics [Internet]. J Alzheim Dis 2017 [cited 2020 Jul 16]. Available from: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad170265.

43. Robertshaw D, Cross A. Experiences of integrated care for dementia from family and carer perspectives: a framework analysis of massive open online course discussion board posts [Internet]; 2017. [cited 2020 Jul 16]. Available from: https://doi.org/10.1177/147130121771999.

44. Mansfield E, Noble N, Sanson-Fisher R, Mazza D, Bryant J. Primary care physicians’ perceived barriers to optimal dementia care: a systematic review [Internet]. The Gerontologist; 2018. https://doi.org/10.1093/geront/gny067 [cited 2020 Jul 16]. Available from:

45. Rousseau F, Keller E, Azouaou N, Jarboui M, Telleria-Bernal L, Simard A, et al. Efficacy of a multidisciplinary specialized care unit in reducing severe Behavioural and Psychological Symptoms of Dementia (BPSD) in patients with major neurocognitive disorders: a retrospective study [Internet]. Am J Geriatr Psychiatr 2019. https://doi.org/10.1016/j.ajgp.2019.01.023 [cited 2020 Jul 16]. Available from:

46. Galvin JE, Valois L, Zweig Y. Collaborative transdisciplinary team approach for dementia care [Internet]. Neurodegener Dis Manag 2014; 4(6): 455–469 [cited 2020 Jul 16]. Available from: https://www.futuraemedicine.com/doi/10.2217/nmt.14.147.

47. Seahill S, Nagaria RA, Curley LE. The future of pharmacy practice perspectives of academics and practitioners from Australia, NZ, United Kingdom, Canada and USA. Res Soc Adm Pharm 2018; 14(12): 1163–1171, 929.

48. Thamby SA, Subramani PJ. Seven-star pharmacist concept of WHO. J Young Pharm 2014; 6(2): 1.

49. Bond C. The need for pharmacy practice research. Int J Pharm Pract 2006; 14: 1–2.

50. Jorgenson D, Lamb D, MacKinnon N. Practice change challenges and priorities: a national survey of practising pharmacists. J Am Pharm J 2011; 144(3): 125–131.

51. Bond C. Pharmacy practice research: evidence and impact. In: Pharmacy practice research methods. New York: Springer; 2015. pp. 1–24.

52. Sibbald B, Roland M. Understanding controlled trials: why are randomised controlled trials important? BMJ 1998; 316(7126): 201.

53. Babar Z, Kousar R, Murtaza G, Azhar S, Khan S, Curley L. Randomized controlled trials covering pharmaceutical care and medicines management: a systematic literature review. Res Soc Adm Pharm 2018; 14(6): 521–539.

54. Gilbert JH, Yan J, Hoffman SJ. A WHO report: framework for action on Interprofessional education and collaborative practice. J Allied Health 2010; 39(3): 196–197.

55. Tan ECK, Stewart K, Elliott RA, George J. Pharmacist services provided in general practice clinics: a systematic review and meta-analysis. Res Soc Adm Pharm 2014; 10(4): 608–622.